GNUBIOTICS
Gnubiotics Sciences SA (Gnubiotics), announced today a strategic partnership agreement with ADM, a global leader in human and animal nutrition. The strategic partnership is centered on the commercialization of innovative microbiome solutions for companion animal health and wellbeing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220504005749/en/
This strategic partnership provides ADM with unique access to cutting edge technologies and a pipeline of microbiome-focused innovation from Gnubiotics.
“We´re excited about this partnership with Gnubiotics, and the capabilities they bring, enabling pet parents to better understand their pets’ microbiome. With this knowledge, ADM can leverage its comprehensive pantry of pet and animal well-being solutions to improve individual pet health through precise nutrition and supplementation.” said Gustavo Zenaide, Vice President ADM Pet & Animal Well-being.
The gut microbiome is essential to the health and well-being of companion animals. Study data from Gnubiotics show Animal Milk Oligosaccharides (A.M.O.s) manufactured by Gnubiotics helped protect the microbiome of dogs from the negative effects of antibiotics. In 2021, Gnubiotics also announced patents covering microbiome-based markers to predict, diagnose and treat feline obesity, a major cause of diabetes and chronic kidney disease (CKD) in felines.
“We are pleased to work with ADM, a global leader in human and animal health and nutrition,” said Yemi Adesokan, CEO and Co-Founder, Gnubiotics. “We have developed products which have functional and clinically demonstrated applications for animal health and well-being. This strategic partnership with ADM is a major accomplishment for Gnubiotics as it represents validation of our science and technology. We are excited to collaborate with ADM to continue to develop and bring to market, data-driven microbiome-targeted solutions.”
About Gnubiotics
Gnubiotics is a Swiss biotech company pioneering the use of glycopeptides as immunomodulatory agents with resulting effects on microbiome and overall health. Our pipeline of microbiome targeted solutions includes GNUBIOME FI, a line of functional ingredients, and AMOBIOME Forte a supplement line designed for immunomodulation, microbiome modulation and microbiome recovery post antibiotic use in companion animals. Beyond its glycopeptide pipeline, Gnubiotics has also developed microbiome biomarkers which offers a view on microbiome health as well as predispositions, onset and progression of microbiome correlated diseases.
About ADM
ADM unlocks the power of nature to enrich the quality of life. We’re a premier global human and animal nutrition company, delivering solutions today with an eye to the future. We’re blazing new trails in health and well-being as our scientists develop groundbreaking products to support healthier living. We’re a cutting-edge innovator leading the way to a new future of plant-based consumer and industrial solutions to replace petroleum-based products. We’re an unmatched agricultural supply chain manager and processor, providing food security by connecting local needs with global capabilities. And we’re a leader in sustainability, scaling across entire value chains to help decarbonize our industry and safeguard our planet. From the seed of the idea to the outcome of the solution, we give customers an edge in solving the nutritional and sustainability challenges of today and tomorrow. Learn more at www.adm.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005749/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HTEC Momentum Recognized as a Clutch Global Honoree and Champion for Fall 20259.12.2025 17:09:00 CET | Press release
HTEC Momentum (formerly Momentum Design Lab), HTEC’s research, product design, management and innovation arm, has earned two of Clutch’s highest distinctions—Global Award honoree and Clutch Champion—reaffirming its ninth straight year as the platform’s top-rated UX agency worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209358771/en/ HTEC Momentum Recognized as a Clutch Global Honoree and Champion for Fall 2025 The Clutch Global Awards honorees are selected based on demonstrated industry expertise and exceptional delivery—evaluated through thousands of verified client reviews published on Clutch. Clutch’s rigorous, case-study-driven review process includes extensive verification to ensure the authenticity and depth of each submission. These distinctions further underscore HTEC Momentum’s position as a top-rated leader in UX strategy, design, and user research, reflecting the consistent satisfaction of our clients
Onego Bio Launches “The Power of Trichoderma reesei” Series to Showcase Innovation, Scale, and Real-World Applications9.12.2025 17:00:00 CET | Press release
Onego Bio, a food ingredient company producing non-animal egg protein with precision fermentation*, today announced the launch of a new expert series titled “The Power of Trichoderma reesei: Building the Future with Fungi.” This multi-part initiative reveals the full potential of Trichoderma reesei, the microbial platform behind Onego’s Bioalbumen®, by spotlighting its scientific strengths, industrial scale, and practical performance across food manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209632524/en/ Headshot of Dr. Sharief Barends The first session, “Why Trichoderma reesei is Precision Fermentation’s Quiet Workhorse,” will be held on December 18, 2025, featuring Dr. Sharief Barends, Head of Research Leiden (Netherlands) and Head of Fungal Genetics at IFF, and Dr. Christopher Landowski, Co-Founder and Chief Technology Officer at Onego Bio. Together, they will explore the research legacy, strengths, and
Guinea Emerges as West Africa's New Digital Transformation Powerhouse9.12.2025 16:53:00 CET | Press release
The Republic of Guinea has reached a decisive turning point as a regional digital power. By hosting the Transform Africa Summit 2025, becoming the first francophone nation to receive this major continental event since its creation in 2013, Guinea confirmed the emergence of Conakry as a new digital innovation hub in West Africa. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209780892/en/ Rose Pola Pricemou, Minister of Posts, Telecommunications and Digital Economy of the Republic of Guinea (Photo: AETOSWire) The numbers break all records: over 7,000 participants from 79 countries, including 47 ministers, 1,552 government representatives, 584 business leaders, over 590 start-ups, and 14 MoUs signed. Never before in the history of the Transform Africa Summit has such mobilisation been accomplished. This unprecedented turnout demonstrates international confidence in Guinea's ability to lead Africa's digital transformation ch
Rapid Medical™ Completes Enrollment in DISTALS Trial Evaluating TIGERTRIEVER 13™ for Distal Vessel Occlusions9.12.2025 16:47:00 CET | Press release
The milestone reflects growing evidence for distal-specific thrombectomy solutions and is reinforced by interim findings that confirmed no safety concerns with TIGERTRIEVER 13. Rapid Medical™, a leading developer of active endovascular devices, announces the completion of patient enrollment in the DISTALS Trial, a multicenter randomized study assessing the TIGERTRIEVER 13™ device in patients with distal medium vessel occlusions (DMVO) in acute ischemic stroke. “DMVO strokes represent up to 40% of ischemic strokes and can cause significant disability, yet their treatment has remained uncertain. Recent neutral results from ESCAPE-MEVO and DISTAL made one thing clear: distal thrombectomy requires devices and trials specifically engineered for distal vessels,” said Dr. Jeffrey Saver of UCLA in California, Principal Investigator of DISTALS. “TIGER 13 and DISTALS bring that dedicated design. Completing enrollment is a major step toward evidence that can truly advance care for these patients.
Suzano Launches Nature Strategy and Reinforces the Strategic Importance of Biodiversity Conservation to the Business9.12.2025 16:41:00 CET | Press release
This initiative brings together science and stakeholder collaboration to drive solutions to biodiversity challenges at scale Suzano, the world’s largest pulp producer, has launched its Nature Strategy, reaffirming the company's commitment to biodiversity and how it guides decision-making within the business. Suzano's operations depend directly on nature, and the company recognizes that its longevity and ability to innovate are intrinsically linked to the health of ecosystems. Therefore, nature occupies a significant strategic role in the business’ vision. The science-led Nature Strategy, developed in collaboration with IUCN, is guided by the mitigation hierarchy: avoid, reduce, restore and transform. This approach enables the prevention of impacts, the minimization of risks, and the promotion of ecosystem regeneration. With support from IUCN, Suzano has pioneered the use of the STAR metric – a tool that enables the company to map sensitive areas within the territories where it operates
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom